Latest News for: compugen

Edit

Other Report or Announcement (Compugen Ltd)

Public Technologies 13 Jul 2026
). The text version of this document is not available ... Disclaimer. Compugen Ltd.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Compugen Ltd)

Public Technologies 13 Jul 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10 ... Washington, D.C ... COMPUGEN LTD [CGEN] 5 ... C/O COMPUGEN LTD., 26 HAROKMIM STREET 3 ... C/O COMPUGEN LTD ... Compugen Ltd.
Edit

Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress (Compugen Ltd)

Public Technologies 18 Jun 2026
). The text version of this document is not available ... Disclaimer. Compugen Ltd.
Edit

Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress

PR Newswire 18 Jun 2026
HOLON, Israel, June 18, 2026 /PRNewswire/ -- Compugen Ltd ... Following the presentation, the poster will be available in the publications section of Compugen's website, www.cgen.com ... About Compugen ... SOURCE Compugen Ltd.
Edit

Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 (Compugen Ltd)

Public Technologies 11 Jun 2026
). The text version of this document is not available ... Disclaimer. Compugen Ltd.
Edit

Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026

PR Newswire 11 Jun 2026
HOLON, Israel, June 11, 2026 /PRNewswire/ -- Compugen Ltd ... Following the presentation, the poster will be available in the publications section of Compugen's website, www.cgen.com. About Compugen ... SOURCE Compugen Ltd.
Edit

Notice of Effectiveness (Form EFFECT) (Compugen Ltd)

Public Technologies 09 Jun 2026
) UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 ... Effectiveness Date ... COMPUGEN LTD ... Compugen Ltd.
Edit

Notice of Effectiveness form f-3 (Compugen Ltd)

Public Technologies 09 Jun 2026
). The text version of this document is not available ... Disclaimer. Compugen Ltd.
Edit

Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development (Compugen Ltd)

Public Technologies 08 Jun 2026
). The text version of this document is not available ... Disclaimer. Compugen Ltd.
Edit

Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development

PR Newswire 08 Jun 2026
About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug ...
Edit

Reports First Quarter 2026 Results (Compugen Ltd)

Public Technologies 18 May 2026
). The text version of this document is not available ... Disclaimer. Compugen Ltd.
Edit

Compugen: Q1 Earnings Snapshot

The Milton Standard Journal 18 May 2026
HOLON, Israel (AP) — HOLON, Israel (AP) — Compugen Ltd. (CGEN) on Monday reported a loss of $7.7 million in its first quarter ....
Edit

Compugen Reports First Quarter 2026 Results (Form 6-K) (Compugen Ltd)

Public Technologies 18 May 2026
Compugen Reports First Quarter 2026 Results · COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027 ... HOLON, ISRAEL, May 18, 2026 - Compugen Ltd.
Edit

Compugen Reports First Quarter 2026 Results

PR Newswire 18 May 2026
HOLON, Israel, May 18, 2026 /PRNewswire/ -- Compugen Ltd ... "Q1 2026 reflects continued execution across all of our programs in line with our strategic priorities," said Eran Ophir, Ph.D., President and CEO of Compugen ... About Compugen.
Edit

First Quarter 2026 Press Release (Compugen Ltd)

Public Technologies 18 May 2026
Compugen Reports First Quarter 2026 Results ... HOLON, ISRAEL, May 18, 2026 - Compugen Ltd ... As of March 31, 2026, Compugen had approximately $134.9 million in cash, cash equivalents, short-term bank deposits, and investment in marketable securities.

Article Search

tools
×
×
×
×